Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients, an Open-label, Randomized, Multicenter, Global Phase 2 Trial

NCT05660967 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT05660967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05660967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients, an Open-label, Randomized, Multicenter, Global Phase 2 Trial
Lead sponsor
Genmab
Phase
Phase 2
Overall status
Terminated
Start date
March 6, 2023
Completion date
June 10, 2026
Enrollment
111 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma